Please use this identifier to cite or link to this item:
|metadata.artigo.dc.title:||Current approaches against Alzheimer's disease in clinical trials|
Ramalho, Teodorico C.
França, Tanos C. C.
|metadata.artigo.dc.subject:||Alzheimer's disease - Treatment|
Doença de Alzheimer - Tratamento
Inibidores da acetilcolinesterase
|metadata.artigo.dc.publisher:||Sociedade Brasileira de Química|
|metadata.artigo.dc.identifier.citation:||KUCA, K. et al. Current approaches against Alzheimer's disease in clinical trials. Journal of the Brazilian Chemical Society, São Paulo, v. 27, n. 4, p. 641-649, 2016.|
|metadata.artigo.dc.description.abstract:||Alzheimer's disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Currently, this disease represents one of the uppermost human issues, both from the medical and economic point of view. Interest in the discovery of a drug for AD is enormous. However, despite the long-term and worldwide effort for a more effective therapy, the only available treatment is a symptomatic use of acetylcholinesterase inhibitors (AChEIs) and memantine. New therapeutic approaches as well as those based on cholinergic or amyloid theory have not brought the desired benefits yet. Thus, the question is whether an effective drug for this progressive disease will ever be developed or whether people will have to rely only on prevention and minimize risk factors of AD.|
|Appears in Collections:||DQI - Artigos publicados em periódicos|
Files in This Item:
|ARTIGO_Current Approaches Against Alzheimer's Disease in Clinical Trials.pdf||1,3 MB||Adobe PDF||View/Open|
This item is licensed under a Creative Commons License